Bay Area Bio-Tech Firms Take Lead In Fight Against Coronavirus
REDWOOD CITY (KPIX 5) — A number of Bay Area biotech companies are working at the forefront of efforts to combat the novel coronavirus.
“All of these people are working on this mission impossible,” said Hesaam Esfandyarpour, the CEO of GenapSys in Redwood City.
The company is testing a new and portable electronic device for DNA sequencing. The device promises to quickly and accurately detect the sequence of the DNA of the novel coronavirus.
“DNA sequencing is effectively the process of reading the code of the DNA. You have the double helix DNA and the ATCG’s and you want to read what the makeup of the DNA is,” said Esfandyarpour.
GenapSys has shrunk the normally refrigerator size DNA sequencing devices into a new form factor that fits into a backpack.
It uses the power of modern microprocessors, instead of bulky optics or lasers, to electronically detect and analyze strains or mutations of the virus.
“It’s showing you molecular level information. Really detailed information on what’s going on,” explained Esfandyarpour. “And you can use that to develop vaccines and the treatment for that, and of course for screening and detection purposes.”
GenapSys is currently in talks with the Chinese Centers for Disease Control to have several devices shipped overseas to support emergency efforts on the ground there.
Meanwhile, doctors at UCSF are working with Mammoth Biosciences in South San Francisco to simplify the diagnostic test for novel coronavirus, which could soon be used in walk in clinics.
“We want to make it a single reaction that can be run in a tube and we want to make the read out similar to a urine pregnancy test where you have a color change to confirm whether or not a patient was infected,” said Dr. Charles Chiu.
The CDC has also now certified 16 state labs in California — including one in Richmond — to test for the novel coronavirus.
Until now, samples had to be sent to a lab in Atlanta, which could take a week to provide results. The new procedure could get results back to California doctors and patients in two days.
The California labs will be able to begin testing on Wednesday.
-
Most popular related searches
Related news
-
CD Genomics Fully Supports Your Microbiome Research with Comprehensive Sequencing Solutions
CD Genomics is a leading services company committed to providing global customers with the most comprehensive analytic services, including a broad range of microbial genomic solutions to support research and development. The company announced microbiome profiling services, alongside bioinformatic analysis technology to help researchers understand the significance of human and animal microbiota. Through long-term and detailed studies of the gut microbiota, scientists have revealed the complex relationship...
-
Creative Proteomics Cytokine Announces Cytokine Systemic Lupus Erythematosus Cytokines Assay Solutions
Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative proteomics recently announced high sensitivity and wide detection range quantitative detection for systemic lupus erythematosus related cytokines and proteins through a variety of technologies. Systemic lupus erythematosus is a typical systemic autoimmune...
-
Creative Proteomics's Targeted Metabolomic Platform Supports Ketone Body Detection
Creative Proteomics is an experienced outsourcing service provider offering professional and high-quality multi-omics services to academic research institutions and pharmaceutical industry. Creative Proteomics offers targeted metabolomics services for the enrichment and accurate quantitative profiling of a specific metabolite in blood, urine or other body fluids and tissues under specific physiological or pathological conditions. Targeted metabolomics is a qualitative and quantitative analysis method for...
-
Bayer extends clinical development program for finerenone with Phase III study in children and adolescents with chronic kidney disease
For children and adolescents with chronic kidney disease (CKD), as for adults, the unmet need is high for new treatments to delay disease progression and preserve kidney function / The Phase III study FIONA will investigate the effect of finerenone in pediatric patients with CKD and severely increased proteinuria Bayer announced today the initiation of the FIONA study, a multicenter, randomized, double-blind, placebo-controlled Phase III study, to investigate the efficacy, safety and pharmacokinetics/pharmacodynam...
-
New data from finerenone clinical trial program reinforces renal and cardiovascular benefits in patients with CKD and T2D independent of baseline therapy
Exploratory analysis of the FIGARO-DKD study with finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, indicated a reduction in renal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as seen in the FIDELIO-DKD study Analysis of the FIDELIO-DKD study highlighted that early reduction of urine albumin-to-creatinine ratio (UACR) with finerenone reduced the risk of cardiovascular events and of disease progression of CKD, underpinning the importance of timely...
Customer comments
No comments were found for Bay Area Bio-Tech Firms Take Lead In Fight Against Coronavirus. Be the first to comment!